Wednesday, Compugen Ltd. (CGEN) reported positive results from a recently completed in vivo study of its novel peptide antagonist, CGEN-25007, a possible treatment for inflammatory diseases and other immune related diseases. CGEN-25007, a novel peptide antagonist of the gp96 protein, was predicted using Compugen's DAC Blockers discovery platform
CGEN-25007 was initially predicted using the company's DAC blockers platform, designed to predict peptides that block proteins of interest from achieving certain disease-associated conformations. The company found that CGEN-25007 binds recombinant gp96 in a dose dependent manner.
The data from the vivo study showed CGEN-25007 to have immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases and other immune related pathologies.
Using an animal model of endotoxemia, CGEN-25007 was shown to exhibit a profound and dose-dependent anti-inflammatory activity.
In this study, the novel peptide was administered following the introduction of lipopolysaccharide, a bacterial substance that induces a strong response in the animal immune system leading to systemic inflammation.
The company said that the administration of CGEN-25007 resulted in a decrease of about 50% in the serum levels of inflammatory cytokines and chemokines, including tumor necrosis factor alpha, IL-6, interferon-gamma, MIP-1a and MIP-2.
Compugen indicated that CGEN-25007 was also found to strongly inhibit the secretion of inflammatory cytokines from human peripheral blood mononuclear cells.
CGEN is currently trading at $2.24, up 12 cents or 5.66%.
For comments and feedback: editorial@rttnews.com